Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment.
+ 1 more risk
Excellent balance sheet with limited growth.
Share Price & News
How has Alligator Bioscience's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 7AL's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 7AL underperformed the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: 7AL underperformed the German Market which returned 15% over the past year.
Price Volatility Vs. Market
How volatile is Alligator Bioscience's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Alligator Bioscience undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 7AL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 7AL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 7AL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 7AL is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 7AL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 7AL is good value based on its PB Ratio (2.5x) compared to the DE Biotechs industry average (3.5x).
How is Alligator Bioscience forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7AL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 7AL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 7AL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 7AL's revenue (75.2% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: 7AL's revenue (75.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 7AL is forecast to be unprofitable in 3 years.
How has Alligator Bioscience performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 7AL is currently unprofitable.
Growing Profit Margin: 7AL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 7AL is unprofitable, and losses have increased over the past 5 years at a rate of -40.1% per year.
Accelerating Growth: Unable to compare 7AL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7AL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 7AL has a negative Return on Equity (-81.28%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Alligator Bioscience's financial position?
Financial Position Analysis
Short Term Liabilities: 7AL's short term assets (SEK206.0M) exceed its short term liabilities (SEK40.9M).
Long Term Liabilities: 7AL's short term assets (SEK206.0M) exceed its long term liabilities (SEK11.7M).
Debt to Equity History and Analysis
Debt Level: 7AL is debt free.
Reducing Debt: 7AL has not had any debt for past 5 years.
Inventory Level: 7AL has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 7AL's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 7AL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 7AL has less than a year of cash runway if free cash flow continues to reduce at historical rates of -41.4% each year
What is Alligator Bioscience's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 7AL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 7AL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 7AL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 7AL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 7AL's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Per Norlén (49yo)
Dr. Per Norlén has been the Chief Executive Officer at Alligator Bioscience AB (publ) since 2015 and served as its Chief Medical Officer from 2010 to January 2018 and was its Vice President of Development. ...
CEO Compensation Analysis
Compensation vs Market: Per's total compensation ($USD0.00) is below average for companies of similar size in the German market ($USD412.37K).
Compensation vs Earnings: Per's compensation has increased whilst the company is unprofitable.
|Chief Executive Officer||5.1yrs||kr2.60m||0.17% SEK100.0k|
|Chief Financial Officer||4.1yrs||no data||0.070% SEK42.4k|
|Chief Operating Officer||0.08yrs||no data||no data|
|Director of Investor Relations & Communications||0yrs||no data||no data|
|Senior Vice President of Preclinical Development||19.1yrs||no data||0.14% SEK84.8k|
|Chief Medical Officer||2.1yrs||no data||no data|
Experienced Management: 7AL's management team is considered experienced (4.1 years average tenure).
|Non-Independent Director||19.1yrs||kr275.00k||1.68% SEK1.0m|
|Independent Director||19.1yrs||kr303.00k||0.57% SEK345.9k|
|Independent Chairman||6.1yrs||kr500.00k||no data|
|Independent Director||0.8yrs||no data||no data|
|Independent Director||5.1yrs||kr303.00k||9% SEK5.4m|
|Independent Director||4.1yrs||kr392.00k||no data|
|Independent Director||2.8yrs||kr295.00k||0.044% SEK26.3k|
|Independent Director||0.8yrs||no data||no data|
Experienced Board: 7AL's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Alligator Bioscience AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Alligator Bioscience AB (publ)
- Ticker: 7AL
- Exchange: DB
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr637.500m
- Listing Market Cap: kr60.528m
- Shares outstanding: 71.39m
- Website: https://www.alligatorbioscience.se
Number of Employees
- Alligator Bioscience AB (publ)
- Medicon Village
- Scheelevagen 2
- Skåne County
- 223 81
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ATORX||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Nov 2016|
|7AL||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||Nov 2016|
|ATORXS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Share Capital||GB||SEK||Nov 2016|
|0RK9||LSE (London Stock Exchange)||Yes||Share Capital||GB||SEK||Nov 2016|
|ALLG.F||OTCPK (Pink Sheets LLC)||Yes||Share Capital||US||USD||Nov 2016|
Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment. It develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and bispecific fusion format for the development of novel dual-action antibodies. The company develops ADC-1013, an immunostimulatory antibody, which is in Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial for tumor-directed treatment of metastatic cancer. Its drug candidates in preclinical development stage include ATOR-1017, an immunostimulatory antibody that binds to the costimulatory receptor 4-1BB (CD137) in tumor-specific T cells; ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer; and ATOR-1144, a bispecific antibody for treating solid tumors and hematologic malignancies. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in Biosynergy (AC101), a preclinical project. It has operations in the United States, Sweden, Asia, and internationally. The company has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a license agreement with Janssen Biotech, Inc. for developing ADC-1013. Alligator Bioscience AB (publ) was founded in 2001 and is headquartered in Lund, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/16 22:48|
|End of Day Share Price||2020/02/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.